ETON
Eton Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow +6.3% ·
net new positions +7.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +17 | 8.66M | $313.25M | +19 | −2 |
| Q1 2026 | 53 | 0 | 6.86M | $169.02M | +7 | −7 |
| Q4 2025 | 53 | +3 | 7.09M | $119.84M | +3 | n/a |
| Q3 2025 | 13 | +1 | 6.27M | $136.34M | +1 | n/a |
| Q2 2025 | 9 | -2 | 4.42M | $63.03M | +1 | −3 |
| Q1 2025 | 8 | +2 | 1.18M | $15.27M | +3 | −1 |
| Q4 2024 | 6 | +2 | 854.61K | $11.39M | +2 | n/a |
| Q3 2024 | 3 | -1 | 376.73K | $2.26M | +1 | −2 |
| Q2 2024 | 4 | n/a | 363.35K | $1.20M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.70M | +11.3% | $37.04M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | The Vanguard Group ✦ (passive) | 1.34M | +2.4% | $29.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | JPMorgan Chase ✦ | 702.83K | n/a | $15.27M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 4 | Morgan Stanley ✦ | 586.05K | n/a | $12.73M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (passive) | 574.03K | -3.2% | $12.48M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 438.44K | +35.7% | $9.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 324.62K | -20.0% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 286.42K | +33.5% | $6.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 190.16K | n/a | $4.13M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 88.22K | +202.0% | $1.92M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 11 | Millennium Management ✦ | 15.86K | New | $344,681 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 13.52K | +5.3% | $294,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 5.69K | +1151.4% | $123,735 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $344,681 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 115 holders, 17.61M shares, $424.10M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.17K sh · $229,406
Director · 36.39K sh · $2.13M
Director · 13.48K sh · $811,932
Director · 128 sh · $7,907
Officer · 25.00K sh · $1.63M
Officer, Director · 47.31K sh · $2.85M
Officer, Director · 36.37K sh · $2.22M
Officer, Director · 7.34K sh · $456,085
Officer, Director · 8.98K sh · $562,472
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology